Skip to main content
Acta Radiologica Open logoLink to Acta Radiologica Open
. 2026 Sep 22;15(9):20584601261491165. doi: 10.1177/20584601261491165

CT referrals and cancer detection in patients referred by general practitioners with non-specific symptoms and signs of cancer: A retrospective study

Noa Larsen Ohana 1,2, Josefine Axelsen 1,2, Maja Sundahl Wilkinson 1,2, Ole Graumann 1,2,✉, Kim Sivesgaard 1,2, Thomas Winther Buus 2, Peter Vedsted 3,4, Anette Midtgaard 2, Stine Bisgaard Greve 1, Solveig Kärk Abildtrup Larsen 1,2,✉
PMCID: PMC13745819  PMID: 43005528

Abstract

Background

In Denmark, since 2011-2012, a national cancer patient pathway (CPP) has been in place for patients presenting with non-specific signs or symptoms of and signs of cancer (NSSC). Many cancer patients initially do not display organ-specific alarm symptoms when examined by general practitioners (GPs).

Purpose

To characterize referral symptoms in patients undergoing contrast-enhanced CT chest-abdomen-pelvis (TAP) for non-specific signs of cancer or vague symptoms, in relation to radiological findings and final diagnoses. Second, the study assessed diagnostic accuracy of CT TAP for detecting malignancy in these patient groups.

Materials and Methods

This retrospective cohort study included all patients referred by GPs to CT TAP at Aarhus University Hospital, Denmark through NSSC or vague cancer symptoms from May to August 2024. Referral symptoms and radiology reports were compared to final clinical diagnosis at the end of NSSC-CPP.

Results

The study included 725 patients. The most frequent referral symptoms were weight loss (51.3%), pain (45.0%), and fatigue (39.4%). CT TAP reports indicated that 20.6% of cases had findings suggestive of cancer, most commonly lung cancer. Overall, 9.2% received a malignant diagnosis, most commonly lymphoma or lung, pancreatic, and colorectal cancer, while 11.3% received a benign diagnosis. Cancer was rare in patients with vague symptoms.

Conclusion

This study demonstrates that CT TAP is a valuable tool for diagnosing patients with non-specific signs or symptoms of cancer in general practice. These findings support the continued use of CT TAP within the cancer pathway as an important tool for identifying patients who need further investigation.

Keywords: neoplasms, general practice, computed tomography, referral and consultation, diagnostic cancer pathway, non-specific symptoms

Introduction

Denmark introduced the organ-specific cancer patient pathways (CPPs) in 2007-2008 (known as group 1) due to a poorer cancer outcome compared to other countries. 1 The goal was to optimize diagnostics and enable earlier cancer detection. 2 However, only about half of cancer patients were initially identified as having organ-specific alarm symptoms, leaving the rest without access to an organ-specific CPP. 3 Consequently, a new CPP for patients presenting with non-specific symptoms and signs of cancer (NSSC-CPP) was established in 2011-2012 4 (known as group 2). According to the Danish guidelines, the NSSC-CPP consists of two steps. First, the general practitioner (GP) gathers a thorough medical history, performs a physical examination and orders basic blood and urine tests (filter function). If suspicion for cancer remains, the GP orders imaging. Typically, this involves a contrast-enhanced computed tomography of the chest, abdomen, and pelvis (CT TAP). An image example is provided in Figure 1.

Figure 1.

Figure 1.

Image example in a 56-year-old female with several months of abdominal discomfort. Contrast-enhanced computed tomography of the chest (a), abdomen, and pelvis including the upper abdomen in both arterial (b) and venous (c) phase in accordance with the local standardized protocol.

If the imaging does not provide a clear explanation but suspicion persists, the GP may refer the patient to one of the 21 Diagnostic Centres across Denmark.5,6 At the Diagnostic Centres, physicians from various clinical specialities are responsible for coordinating additional investigations. While national guidelines provide a standardized framework, there is recognized variation in clinical practice, such as the timing of patient admission to a Diagnostic Centre and the preferred imaging modalities. 7 National guidelines specify a maximum of 30 calendar days from initial suspicion to completed assessments, including no more than 22 days from referral to imaging and final diagnosis. 8

Patients presenting with NSSC are classified as group 2 within the Danish CPP. Patients who do not meet the criteria for group 2 but still present with vague or low-risk symptoms – often described as “low-but-not-no-risk” – are classified as group 3 patients.9–11 In 2024, a total of 9897 patients who completed the preliminary diagnostic work-up were referred to the NSSC-CPP pathway 12 (approx. 0.2% of the Danish population).

This study aimed to characterize symptoms at referral in patients undergoing contrast-enhanced CT TAP for non-specific signs of cancer (group 2) or vague symptoms (group 3) in relation to radiological findings and the final diagnoses. Second, the study assessed the diagnostic accuracy of CT TAP for detecting malignancy in this patient group.

Materials and Methods

Approval

The study protocol was approved by the institutional review board at Aarhus University Hospital, Denmark, as a quality assessment study (no. 1-49--72-4-18, 2024). Due to the study's retrospective nature, a waiver of informed consent was given. Clinical CT-images are published with written consent from the patient

Study design and patient population

The study was a retrospective single centre cohort study and included all patients aged 18 years or more who were referred by their GP and underwent a CT TAP for NSSC or vague symptoms, at Aarhus University Hospital, Denmark, between May 1st 2024 and August 31st 2024. All consecutive CT examinations with a completed radiology report were included. Patients from rejected referrals and cancelled bookings were not included.

The patient population was categorized based on their referral pathways used by GPs: Group 2 consisted of patients referred through the NSSC-CPP (referral text referencing NSSC-CPP or group 2). Group 3 consisted of patients whom the GPs associated with “low-but-not-no-risk.” If the referral text did not specify a group or NSSC-CPP, it was named “group unknown.” Group 1 referrals (organ-specific CPP referrals) were excluded.

Dates, referral texts, patient age, and radiologist reports were retrieved from the Radiology Information System (Philips RIS, the Netherlands). The local CT protocol included an arterial phase of the thorax and upper abdomen and a portal venous phase of the abdomen and pelvis, thereby visualizing the upper abdomen in both phases.

Data on final diagnosis, comorbidities, and previous cancer history were retrieved from the electronic patient record system (MidtEPJ, Systematic A/S, Denmark). These variables were either found as a diagnosis code or as mentioned in the patient file. Information on the final diagnosis, for example, consensus from a multidisciplinary team conference (often including both final diagnosis and treatment plan), histopathology, and registration of a relevant diagnosis code was retrieved. Previous cancer history and comorbidities were either found as a diagnosis code or as mentioned in the patient file.

All data were stored and managed in REDCap (Vanderbilt University, US, hosted at Aarhus University, Denmark).

Outcomes

All symptoms mentioned in the referral text were included, regardless of their classic association with cancer.

The CT TAP results were classified according to the radiologist’s description: normal CT, suspected malignant finding, non-malignant finding related to symptoms, and non-malignant finding not related to symptoms. The final diagnosis was divided into three groups: no diagnosis, malignant diagnosis, and non-malignant diagnosis.

Previous cancer history was defined as none, previous cancer (incl. type), or currently in therapy/treatment for known cancer.

Comorbidity was grouped in hypertension, cardiovascular disease, musculoskeletal degenerative disease, chronic respiratory disease, osteoporosis, psychiatric disorders, and others (incl. diabetes).

The time from referral to diagnosis was calculated as the number of days between the date of the GP referral and the date of the multidisciplinary team conference’s consensus on the diagnosis.

Statistical analysis

All analyses were performed in RStudio (Posit, US) using de-identified data. Descriptive statistics were applied to summarize patient demographics, referral symptoms, radiological findings, and final diagnoses. Continuous variables were reported as medians with interquartile ranges, while categorical variables were presented as frequencies and percentages.

Diagnostic accuracy of CT TAP was assessed using the final clinical diagnosis at the end of the NSSC-CPP as the reference standard.

Results

The study population comprised 725 patients with 725 CT scans. Patient characteristics and comorbidities are listed in Table 1. A total of 119 patients (16.4%) had a previous cancer diagnosis, most commonly breast cancer with a total of 32 patients (25.6%), colorectal cancer with 21 patients (16.8%), skin cancer with 15 patients (12.0%), or prostate cancer with 14 patients (11.2%). In total, 6 patients (0.8%) were receiving treatment for an active malignancy at the time of referral for the new CT scan.

Table 1.

Patient characteristics for all referred patients and in the different referral groups. Group 2: CT TAP through NSSC-CPP; group 3: “low-but-not-no-risk” symptoms at referral.

Characteristic Total patients Group 2 Group 3 Group unknown
n (%) 725 (100.0%) 659 (90.9%) 29 (4.0%) 37 (5.1%)
Mean age (SD) 66 (15) 67 (15) 60 (16) 64 (19)
Female sex (%) 394 (54.3%) 364 (55.2%) 17 (58.6%) 17 (45.9%)
Comorbidities n (%)
Hypertension 235 (32.4%) 216 (32.8%) 10 (34.5%) 9 (24.3%)
Cardiovascular disease 208 (28.7%) 193 (29.2%) 6 (20.7%) 9 (24.3%)
Musculoskeletal degenerative disease 149 (20.6%) 135 (20.5%) 8 (27.6%) 6 (16.2%)
Chronic respiratory disease 123 (17.0%) 112 (17.0%) 4 (13.8%) 7 (18.9%)
Osteoporosis 108 (14.9%) 98 (14.9%) 2 (6.9%) 8 (21.6%)
Psychiatric disorder 104 (14.3%) 92 (14.0%) 4 (13.8%) 8 (21.6%)
Other 217 (29.9%) 199 (30.2%) 6 (20.7%) 12 (32.4%)

CT TAP, computed tomography of chest, abdomen, and pelvis; NSSC-CPP, cancer patient pre-planned pathway for non-specific symptoms or signs of cancer.

A total of 659 (90.9%) referrals were in group 2, and 29 (4.0%) were in group 3. The remaining 37 (5.1%) referrals were categorized as group “unknown.” Tables 2 and 3 summarize suspected malignancy and final diagnoses across the different referral groups.

Table 2.

Outcomes from the CT TAP for all and the different patient groups incl. Suspected cancer types by the radiologist and final cancer diagnosis. Group 2: CT TAP through NSSC-CPP; group 3: “low-but-not-no-risk” symptoms at referral.

​ Total Group 2 Group 3 Group unknown
n (%) 725 (100.0%) 659 (90.9%) 29 (4.0%) 37 (5.1%)
Cancer suspicion on CT TAP 149 (20.6%) 141 (21.4%) 5 (17.2%) 3 (8.1%)
Malignant diagnosis 67 (9.2%) 66 (10.0%) 1 (3.4%) 0 (0.0%)
Benign diagnosis based on histopathology 82 (11.3%) 76 (11.5%) 3 (10.3%) 3 (8.1%)
Most frequently suspected cancers Lung (44) (6.1%)
Pancreatic (17) (2.3%)
Colorectal (17) (2.3%)
Lymphoma (17) (2.3%)
Lung (43) (6.5%)
Pancreatic (17) (2.6%)
Colorectal (17) (2.6%)
Lymphoma (13) (2.0%)
Lymphoma (2) (6.7%)
Adrenal gland (1) (3.4%)
Breast (1) (3.4%)
Lung (1) (3.4%)
Lymphoma (2) (5.4%)
Unknown (1) (2.7%)
Most frequently diagnosed cancers Pancreatic (10) (1.4%)
Lung (10) (1.4%)
Colorectal (8) (1.1%)
Lymphoma (8) (1.1%)
Breast (5) (0.7%)
Pancreatic (10) (1.5%)
Lung (10) (1.5%)
Colorectal (8) (1.2%)
Lymphoma (7) (1.1%)
Breast (5) (0.8%)
Lymphoma (1) (3.4%) 0 (0.0%)

CT TAP, computed tomography of chest, abdomen, and pelvis; NSSC-CPP, cancer patient pre-planned pathway for non-specific symptoms or signs of cancer.

Table 3.

Distribution of CT TAP findings compared to the result of the NSSC-CPP.

​ CT TAP findings (n = 725)
Normal CT TAP Suspected malignant finding Non-malignant finding related to symptoms Non-malignant finding, not related to symptoms
Final result of the NSSC-CPP No diagnosis 449 52 25 50
Malignant diagnosis 0 64 2 1
Non-malignant diagnosis 4 33 26 19

CT TAP, computed tomography of chest, abdomen, and pelvis; NSSC-CPP, cancer patient pre-planned pathway for non-specific symptoms or signs of cancer.

Overall, the radiologist reported cancer suspicion based on CT TAP in 149 (20.6%) of the referred patients. A malignant diagnosis was found in 67 (9.2%) of the total patients, while a benign diagnosis was found in 82 (11.3%) of the total patient cohort.

Radiologists reported a non-malignant finding in 123 patients (17.0%) of which 53 (43.1%) were consistent with the referral symptoms. In the remaining patients with non-malignant findings, the referral symptoms could not be explained by the CT findings.

The median duration from referral to diagnosis was 23 days (interquartile range 14-33). Most patients, 708 (97.7%), received contrast-enhanced CT scans. Overall, 140 patients (19.3%) had previous NSSC-CPP and CT examinations at least once. Within 30 days of referral, four patients (0.6%) passed away.

The median number of symptoms at referral was 3 (IQR 2-4) with the most common symptoms being weight loss in 372 patients (51.3%), pain in 326 patients (45.0%), fatigue in 286 patients (39.4%), and abnormal lab results in 213 patients (29.4%) (Figure 2). Cancer was less frequent in patients presenting with one or two symptoms (Figure 3).

Figure 2.

Figure 2.

Distribution of symptoms reported at referral from general practice. For each symptom, the blue bar represents the number of patients referred with the symptom, and the red bar represents the number of malignant diagnoses among these patients. Patients typically had more than one symptom registered.

Figure 3.

Figure 3.

Number of patients stratified by symptom count at referral, along with the corresponding patient count of each diagnostic outcome.

Discussion

This study found that patients referred via the Danish NSSC-CPP primarily presented with symptoms like weight loss and pain. Most of the referred patients belonged to group 2. For group 2, one in ten had a cancer, whereas one in thirty in group 3 (low-but-not-no-risk) had cancer. Overall, 20.6% of patients were flagged for cancer based on CT TAP results, with 9.2% confirmed to have malignancies, most commonly pancreatic or lung cancer (Table 2).

The finding that weight loss is the most common symptom (Figures 2 and 4) is consistent with most of the existing literature on patients referred to NSSC-CPP (9-12). However, weight loss is not a very precise predictor of cancer, especially not weight loss of 1-10 kg. Weight loss of 16 kg or more was more likely to be associated with malignancy compared to 1-10 kg. For example, almost half of the patients referred with a weight loss of 20+ kg in this study received a malignant diagnosis. The weight loss in referral texts is likely an estimate rather than an exact measurement, and body weight is known to fluctuate, for example, during the menstrual cycle or due to variations in diet.13,14 In addition, some cardiovascular diseases are associated with body weight variability, which could be a contributing factor since 28.5% of the patients in our study had this comorbidity. 15

Figure 4.

Figure 4.

Final diagnoses stratified by severeness of reported weight loss. No diagnosis (light blue), malignant diagnosis (red), and benign diagnosis (blue).

The malignancy rate in this study (9.2%) was lower than in similar studies on NSSC-CPP, which report rates ranging from 11% to 22%.10–12,16–19 Many of these studies were conducted in the early years following the implementation of the cancer pathway, which may partly explain the higher prevalence.10–12,16–18 This observation aligns with the suggestion that the prevalence should decrease over time as the GPs become more familiar with the referral pathway. 18 Another potential explanation for the observed difference is that most current literature on NSSC-CPP, including the largest study, is based on patients referred to Diagnostic Centres.10–12,20 Discrepancies between national Danish guidelines and routine clinical practice regarding Diagnostic Centres may also contribute. 5

Only one patient in group 3 was diagnosed with malignancy. Additionally, group 3 accounted for just 4.0% of the 725 referrals, indicating limited use. This suggests that some patients with vague symptoms may have been classified as group 2, consistent with the broad referral criteria outlined in the NSSC-CPP guidelines. A study on the use of CPPs in primary care across Denmark indicates that 50% of cancer patients present without “alarm” symptoms at presentation. 3 In Table 2, the referral patterns of group “unknown” and group 3 are similar, suggesting that some patients in group “unknown” may have been intended for group 3.

The types of cancer suspected by radiologists and confirmed (Table 2) showed alignment between the suspected and confirmed types of cancer, partly consistent with findings from previous studies in the field. These studies reported a broad spectrum of common malignancies as final outcomes, with several identifying digestive system cancer, including pancreatic cancer, as highly prevalent.9–11,19–21 Additionally, respiratory system cancer/lung cancer is also frequently reported,9,11,17,19,20 and haematological or lymphoid malignancies appear consistently across multiple studies.9–11,17,18,20 One study also highlights breast cancer and malignant melanoma as common cancer outcomes. 18 A possible explanation for lung cancer being the most suspected diagnosis in our study is its wide spectrum of early radiological presentations. 22 For pancreatic cancer, the high prevalence in our study may reflect its tendency to present with subtle and non-specific symptoms such as weight loss and abdominal pain until later stages.23,24

A significant finding in this study was that 19.3% of patients had previously undergone NSSC-CPP or had been referred as group 3 at least once. This raises important questions about the value and efficiency of repeated imaging in patients with non-specific symptoms. Although multiple imaging sessions might help detect malignancies earlier in certain cases, they also entail extra costs, radiation risks, and possible increased patient anxiety. Future studies should focus on identifying the most cost-effective management strategies for these patients.

CT TAP is a valuable tool for detecting malignancy in patients referred on suspicion of occult cancer. While a negative CT TAP can largely reassure both clinicians and patients, a positive finding may lead to further investigations, referrals, and an overall prolonged diagnostic pathway. Previous research on defensive medicine found that 8% of defensive actions involve ordering diagnostic imaging and 20% involve referring the patient, 25 suggesting that a low threshold for further work-up may contribute to over-investigation. Moreover, a qualitative study highlights potential harms, including patient worry associated with participation in the diagnostic pathway. 26

False negative findings were rare in this study. The three false negative cases involved malignancies that were notoriously difficult to detect on CT: a lymphoma with non-specific splenomegaly as the only visible sign, a gastric cancer diagnosed at subsequent gastroscopy, and lung cancer disguised by pleural effusion. These are all good examples of limitations in the detection of certain cancers on CT and not suggestive of substandard imaging or interpretation.

This study benefits from several strengths, although certain limitations should also be acknowledged. One major strength is that this study included only GP referrals, excluding internal referrals from hospital departments. Furthermore, because the patients were often referred for CT TAP before Diagnostic Centre assessment, referrals from Diagnostic Centres were excluded. This allowed the study to focus on the initial diagnostic process in general practice when utilizing this part of the filter function.

A limitation of this study is that referrals were written in non-standardized plain text, some short and others long and detailed. Another limitation was that additional patient courses, including malignant diagnoses, could only be identified, if patients passed through the hospital system. Some benign diagnoses might have been managed and treated by the GP. When booking CT TAP, our institution treats patients in groups 2 and 3 the same way, using the same protocol and time slots, making them difficult to distinguish. Additionally, NSSC-CPP lacks a specific detection target, making it difficult to determine whether our cancer detection rates are optimal. Finally, this study is limited by its low statistical precision, especially in group 3. Generally, further research is needed to better understand group 3 patients, as highlighted elsewhere. 20

We believe that our results are transferable to other countries and healthcare systems although the frequency of malignant cancers will vary slightly depending on the pathway for identifying and preselecting patients with non-specific symptoms and signs of cancer.

In conclusion, CT TAP is a valuable tool for diagnosing cancer in patients with non-specific, serious symptoms in general practice. These findings support the continued use of CT TAP within the cancer pathway as an important tool for identifying patients who need further investigation.

Footnotes

Author contributions: NLO: Design, data collection, analysis, and first and final draft.

JA: Data collection and second and final draft.

MW: Data collection and second and final draft.

OG: Design, analysis, first, second, and final draft.

KS: Design and second and final draft.

TWB: Design and second and final draft.

PW: Analysis and second and final draft.

AM: Design and second and final draft.

SBG: Design and second and final draft.

SKAL: Design, data collection, analysis, first, second, and final draft.

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Ole Graumann: Has received speaker honorariums from GE Healthcare and Boston Scientific. Has received research grants from Boston Scientific. Has received royalties from Munksgaard. Advisory Board at Boston Scientific and Bayer. The remaining authors declare no conflicts of interest.

ORCID iDs

Kim Sivesgaard https://orcid.org/0000-0001-6336-9890

Thomas Winther Buus https://orcid.org/0000-0003-4801-6389

Solveig Kärk Abildtrup Larsen https://orcid.org/0000-0001-5482-7650

References

  • 1.Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the international cancer benchmarking partnership): an analysis of population-based cancer registry data. The Lancet (British edition) 2011; 377: 127–138. 10.1016/S0140-6736(10)62231-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians--a national Danish project. Health Policy 2012; 105: 65–70. 10.1016/j.healthpol.2011.11.001 [DOI] [PubMed] [Google Scholar]
  • 3.Jensen H, Tørring ML, Olesen F, et al. Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study. BMC Cancer 2014; 14: 636. 10.1186/1471-2407-14-636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sundhedsstyrelsen: diagnostisk pakkeforløb (the Danish health authority: diagnostic patient pathways) 2022. https://www.sst.dk/media/1odjlxo2/diagnostisk-pakkeforloeb_final_-opdateret-dec-2023docx.pdf. (accessed 22nd June 2026).
  • 5.Damhus CS, Siersma V, Dalton SO, et al. Non-specific symptoms and signs of cancer: different organisations of a cancer patient pathway in Denmark. Scand J Prim Health Care 2021; 39: 23–30. 10.1080/02813432.2021.1880094 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Blinded for anonymity.
  • 7.Danske Regioner . Gruppe 3 – billeddiagnostik af patienter med vage symptomer, hvor alvorlig sygdom ikke kan udelukkes (danish regions: imaging in group 3 patients) 2022, (accessed 22nd June 202auh). https://www.sundhed.dk/sundhedsfaglig/information-til-praksis/midtjylland/almen-praksis/patientbehandling/patientforloeb/forloebsbeskrivelser-icpc/a-alment-og-uspecificeret/paraklinisk-billeddiagnostik-hos-patienter-med-vage-symptomer/
  • 8.Sundhedsstyrelsen (The Danish Health Authority) . Monitorering af forløbstider på kræftområdet - årsrapport 2024. https://www.sst.dk/udgivelser/2025/monitorering-af-forloebstider-paa-kraeftomraadet-aarsrapport-2024 (2025), accessed 22nd June 2026.
  • 9.de Chiffre JMD, Ormstrup TE, Kusk MW, et al. Patients from general practice with non-specific cancer symptoms: a retrospective study of symptoms and imaging. BJGP Open 2024; 8, BJGPO.2023.0058. 10.3399/BJGPO.2023.0058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bislev LS, Bruun BJ, Gregersen Set al. Prevalence of cancer in Danish patients referred to a fast-track diagnostic pathway is substantial. Danish medical journal. 2015; 62. [PubMed] [Google Scholar]
  • 11.Næser E, Fredberg U, Møller H, et al. Clinical characteristics and risk of serious disease in patients referred to a diagnostic centre: a cohort study. Cancer epidemiology 2017; 50: 158–165. 10.1016/j.canep.2017.07.014 [DOI] [PubMed] [Google Scholar]
  • 12.Jørgensen SF, Ravn P, Thorsen S, et al. Characteristics and outcome in patients with non-specific symptoms and signs of cancer referred to a fast track cancer patient pathway; a retrospective cohort study. BMC Cancer 2017; 17: 809–811. 10.1186/s12885-017-3826-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Strohacker K, Carpenter K, McFarlin B. Consequences of weight cycling: an increase in disease risk? International journal of exercise science 2009; 2: 191–201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kanellakis S, Skoufas E, Simitsopoulou E, et al. Changes in body weight and body composition during the menstrual cycle. Am J Hum Biol 2023; 35: e23951. 10.1002/ajhb.23951 [DOI] [PubMed] [Google Scholar]
  • 15.Massey RJ, Siddiqui MK, Pearson ER, et al. Weight variability and cardiovascular outcomes: a systematic review and meta-analysis. Cardiovasc Diabetol 2023; 22: 5–12. 10.1186/s12933-022-01735-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Møller M, Juvik B, Olesen SC, et al. Diagnostic property of direct referral from general practitioners to contrast-enhanced thoracoabdominal CT in patients with serious but non-specific symptoms or signs of cancer: a retrospective cohort study on cancer prevalence after 12 months. BMJ Open 2019; 9: e032019. 10.1136/bmjopen-2019-032019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ingeman ML, Christensen MB, Bro F, et al. The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer–a cross-sectional study of patient characteristics and cancer probability. BMC Cancer 2015; 15: 421. 10.1186/s12885-015-1424-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Moseholm E, Lindhardt B. Patient characteristics and cancer prevalence in the Danish cancer patient pathway for patients with serious non-specific symptoms and signs of cancer-A nationwide, population-based cohort study. Cancer Epidemiol 2017; 50: 166–172. 10.1016/j.canep.2017.08.003 [DOI] [PubMed] [Google Scholar]
  • 19.Rømer Skøtt M, Jensen RFG, Nielsen RB, et al. Diagnostic accuracy of CT in patients with non-specific symptoms of cancer referred directly to CT from general practice: a retrospective follow-up study. BJGP Open 2025: 0077. [DOI] [PubMed] [Google Scholar]
  • 20.Grønnemose RB, Hansen PS, Worsøe LS, et al. Risk of cancer and serious disease in Danish patients with urgent referral for serious non-specific symptoms and signs of cancer in funen 2014–2021. Br J Cancer 2024; 130: 1304–1315. 10.1038/s41416-024-02620-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ormstrup TE, Rafaelsen SR, Pedersen MRV. Cancers detected by thoracoabdominal computed tomography in patients with nonspecific symptoms. Danish medical journal 2021; 68: A03210195. [PubMed] [Google Scholar]
  • 22.Iwasawa T, Takemura T, Ogura T. Smoking-related lung abnormalities on computed tomography images: comparison with pathological findings. Jpn J Radiol 2018; 36: 165–180. 10.1007/s11604-017-0713-0 [DOI] [PubMed] [Google Scholar]
  • 23.Virgilsen LF, Rasmussen LA, Vedsted P, et al. Diagnosing pancreatic cancer in general practice: a cross-sectional study on associations between suspicion of cancer, urgent referral and time to diagnosis. Scand J Prim Health Care 2022; 40: 78–86. 10.1080/02813432.2022.2036491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. The cancer journal (Sudbury, Mass) 2017; 23: 333–342. 10.1097/PPO.0000000000000290 [DOI] [PubMed] [Google Scholar]
  • 25.Andersen MK, Hvidt EA, Pedersen KM, et al. Defensive medicine in Danish general practice. Types of defensive actions and reasons for practicing defensively. Scand J Prim Health Care 2021; 39: 413–418. 10.1080/02813432.2021.1970945 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Damhus CS, Brodersen JB, Risør MB. Luckily—I am not the worrying kind: experiences of patients in the Danish cancer patient pathway for non-specific symptoms and signs of cancer, Health (London, England, 1997) 2023;27: 1059–1075. [DOI] [PubMed] [Google Scholar]

Articles from Acta Radiologica Open are provided here courtesy of SAGE Publications

RESOURCES